Best in Biotech 22 Apr 2025
Seven biotechs to watch in the hepatitis B space
Here we take a look at seven biotechs with clinical drug candidates on a quest to win regulatory approval to treat HBV.
About
Having completed a master’s programme in International Journalism from Cardiff University in 2022, I have written about various subjects including culture, politics, social justice, mental health, LGBTQ+ issues and gender. My undergraduate degree in life sciences has equipped me to explore my passion for reporting on health, science and the environment. When I’m not transcribing interviews and fretting about deadlines, I like to spend my time reading, watching movies, and making lousy mixtapes for a potential side career in rap music.
Articles by Roohi Mariam Peter
In Depth 17 Apr 2025
Biomaterials in construction: meet the startups reinventing our buildings
We will explore the various biomaterials making a mark in the construction field and how biotechs could potentially transform a carbon-intensive industry.
In Depth 9 Apr 2025
Cystic fibrosis: is the next blockbuster a gene therapy?
Learn about the biotechs progressing their gene therapies for cystic fibrosis and why it might just be the breakthrough that patients need.
News and Trends 2 Apr 2025
Top biotech deals of March 2025
Learn about the top biotech deals of March 2025. Small molecules, bispecific antibodies, and protein therapies were all part of major collaborations.
News and Trends 31 Mar 2025
AstraZeneca bets on Asia: a surge of deals in March amid fraud probe
AstraZeneca has vowed to spend over $10 billion in Asia, particularly in China, to build Beijing into an R&D hub amid probe into fraud scandals.
Best in Biotech 25 Mar 2025
These 7 biotechs are shaping the next generation of endometriosis care
As we observe Endometriosis Awareness Month in March, let us take a look at seven biotechs advancing promising candidates in the clinic.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 24 Mar 2025
First-ever RIPTAC enters clinic: all you need to know about this new cancer approach
The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.
News and Trends 21 Mar 2025
Depression drug trials are failing—and placebos are to blame
In this article, we examine recent clinical trial failures and discuss potential pathways forward for antidepressant drug research.
Best in Biotech 18 Mar 2025
Cancer vaccines: 11 biotechs to keep an eye out for
As various biotechs across the world specialize in the production of cancer vaccines, here are 11 companies making progress in the field.
Best in Biotech 13 Mar 2025
Nine biotechs thriving in Seattle in 2025
In this article, let us take a look at some of the major biotech companies in Seattle that are contributing to the biotech industry at large.
In Depth 12 Mar 2025
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
News and Trends 10 Mar 2025
23andMe: the collapse of a genomics giant
23andMe was once worth $6 billion and is now a penny stock. Layoffs, data breaches, and mass resignations plagued the genomics giant. How did it all unfold?
ADVERTISEMENT
